葵花药业(002737.SZ)：复方聚乙二醇(3350)电解质散取得药品注册证书

Core Viewpoint - The company has received the drug registration certificate for Compound Polyethylene Glycol (3350) Electrolyte Powder from the National Medical Products Administration, which will enable it to accelerate the mass production and market launch of the new product [1] Group 1 - The company plans to expand its product matrix and optimize its product structure layout following the approval [1] - The company aims to leverage its brand resource advantages to enhance market competitiveness [1]